Rhumbline Advisers Hille Vax, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 08, 2025	SELL	$1.45 - $2.14 $3,239 - $4,780	-2,234 Reduced 4.8%	44,294 $70,000
Q4 2024 May 29, 2025	BUY	$1.72 - $2.06 $3,842 - $4,602	2,234 Added 5.04%	46,528 $94,000
Q4 2024 Jan 30, 2025	SELL	$1.72 - $2.06 $3,909 - $4,682	-2,273 Reduced 4.66%	46,528 $94,000
Q3 2024 Nov 12, 2024	BUY	$1.58 - $14.42 $9,705 - $88,582	6,143 Added 14.4%	48,801 $85,000
Q2 2024 Aug 01, 2024	BUY	$11.86 - $15.93 $107,605 - $144,532	9,073 Added 27.02%	42,658 $616,000
Q1 2024 May 09, 2024	BUY	$14.15 - $19.75 $26,205 - $36,577	1,852 Added 5.84%	33,585 $558,000
Q4 2023 Feb 08, 2024	BUY	$10.35 - $17.11 $44,701 - $73,898	4,319 Added 15.75%	31,733 $509,000
Q3 2023 Nov 09, 2023	BUY	$11.59 - $16.7 $9,712 - $13,994	838 Added 3.15%	27,414 $368,000
Q2 2023 Aug 08, 2023	BUY	$12.93 - $18.76 $46,160 - $66,973	3,570 Added 15.52%	26,576 $456,000
Q1 2023 May 11, 2023	BUY	$14.73 - $18.18 $18,088 - $22,325	1,228 Added 5.64%	23,006 $380,000
Q4 2022 Feb 14, 2023	BUY	$13.52 - $21.46 $48,996 - $77,771	3,624 Added 19.96%	21,778 $364,000
Q3 2022 Nov 10, 2022	BUY	$10.5 - $22.01 $11,088 - $23,242	1,056 Added 6.18%	18,154 $310,000
Q2 2022 Aug 11, 2022	BUY	$8.7 - $20.18 $148,752 - $345,037	17,098 New	17,098 $187,000

36.5M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $69.5M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.